PACT通过dRNA结合和二元化抑制PKR激活,是三阴性乳腺癌的治疗标
Addison A Young1, Isabelle G Juhler1, Jackson R Pierce1
1Purdue University.
概括
针对dsRNA结合蛋白PACT的向显示了三阴性乳腺癌 (TNBC) 的治疗潜力. 耗尽PACT会激活PKR传感器,导致癌细胞死亡,并为TNBC治疗提供新的途径.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 三阴性乳腺癌 (TNBC) 是一种缺乏向治疗的侵袭性亚型.
- 激活病毒双链RNA (dsRNA) 传感器可以诱导用于癌症治疗的"病毒模拟".
- ADAR1和PACT是dsrna感应的关键调节者,对癌细胞存活有影响.
研究的目的:
- 调查PACT在TNBC中的作用.
- 探索针对TNBC中PACT和ADAR1的治疗潜力.
- 阐明PACT调节dSRNA感知和细胞死亡的机制.
主要方法:
- 在使用遗传方法的TNBC细胞系中减少ADAR1和PACT.
- 对dsRNA传感器激活 (PKR) 和下游信号通路的评估.
- 细胞活力测定和救援实验,以证实PACT的功能.
主要成果:
- 在TNBC细胞中的PACT枯竭强烈激活PKR,导致细胞死亡.
- 在抑制PKR激活方面,PACT的dsRNA结合和二元化是至关重要的.
- 在抑制dSRNA传感方面,ADAR1和PACT表现出部分冗余的作用.
结论:
- PACT在抑制TNBC中的PKR激活中发挥着至关重要的作用.
- 针对PACT是TNBC的一个有前途的治疗策略.
- 了解PACT-ADAR1-PKR轴为新型癌症治疗提供了洞察力.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K


